1 Min Read
* ANNOUNCES IMMUNE ACTIVATION DATA IN FIRST FOUR PATIENTS TREATED WITH ONCOS-102
* RESULTS ARE IN LINE WITH DATA REPORTED IN COMPLETED ALL-COMERS PHASE I TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.